Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics

Summary

The goal of this exploratory study is understand the mechanisms of response to immunotherapy in Non-Small Cell Lung Cancer patients. The investigators are going to search for correlation between specific biological features and response to immunotherapy, and to use those associations for developing an algorithm enabling to identify patients that could benefit from the immune check inhibitor based anti cancer treatment. Patients will provide biological samples before and during their treatment, and clinical data will be collected.

Detailed Description

The goal of the study is to develop an algorithm that associates between biomarkers detected in biospecimen of NSCLC patients, and their: * Response to treatment * Clinical benefit parameters such as PFS and OS. * Adverse events to immune check inhibitor therapy * Biological mechanisms involved in response or resistance to immune check inhibitor therapy. Patients will provide plasma, PBMCs, stool and tissue samples (where applicable) before and during treatment. Clinical data, including disease history, given treatment, response evaluation and adverse events to the treatment will be recorded. Samples will be analysed as follows - * Proteomic features (Plasma proteomics) * Epigenetic patterns (cell free DNA) * ctDNA mutation analysis * PBMC subpopulations * Microbiome profiling (Stool)

Eligibility Criteria

Interventions